| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 31,736,288 | 6,736,288 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | - |
| Proceeds from exercise of stock options | 1,103,940 | 983,194 |
| Proceeds from employee stock purchase plan | 19,616 | 19,616 |
| Net cash provided by financing activities | 1,123,556 | 1,002,810 |
| Net increase (decrease) in cash and cash equivalents | 4,813,507 | -13,285,823 |
| Cash and cash equivalents at beginning of period | 54,527,092 | - |
| Cash and cash equivalents at end of period | 59,340,599 | - |
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)